Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

AstraZeneca Breast Cancer Study Locator Service 1-877-400-4656
az-bcsl@careboxhealth.com


AstraZeneca Clinical Study Information Center 1-877-240-9479
information.center@astrazeneca.com


Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
Back

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

Recruiting

Open to: ALL

Age: 18.0 - 130.0

Cambridge London Manchester Sutton Oxford London Leeds Leicester London Taunton Aberdeen Shrewsbury Ipswich Northampton Lancaster Warwick Derby Liverpool London Stockton Sutton In Ashfield Burton-on-Trent Whitchurch Bath Reading Guilford Brighton

Medical Conditions

Breast Neoplasms

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy). The planned duration of treatment in either arm within the study will be 7 years.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Oct 2023 Mar 2030

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : Camizestrant. Experimental. Administered orally

Intervention Arm Group : Arm B: camizestrant ± abemaciclib;

Intervention Type : DRUG
Intervention Description : Tamoxifen. Comparator. Administered orally

Intervention Arm Group : Arm A: standard endocrine therapy of investigator´s choice ± abemaciclib;

Intervention Type : DRUG
Intervention Description : Anastrozole. Comparator. Administered orally

Intervention Arm Group : Arm A: standard endocrine therapy of investigator´s choice ± abemaciclib;

Intervention Type : DRUG
Intervention Description : Letrozole. Comparator. Administered orally

Intervention Arm Group : Arm A: standard endocrine therapy of investigator´s choice ± abemaciclib;

Intervention Type : DRUG
Intervention Description : Exemestane. Comparator. Administered orally

Intervention Arm Group : Arm A: standard endocrine therapy of investigator´s choice ± abemaciclib;

Intervention Type : DRUG
Intervention Description : Abemaciclib adjuvant treatment Administered orally

Intervention Arm Group : Arm A: standard endocrine therapy of investigator´s choice ± abemaciclib;Arm B: camizestrant ± abemaciclib;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Research Site
    Cambridge
    CB2 2QQ
  • Research Site
    London
    EC1M 6BQ
  • Research Site
    Manchester
    M20 4BX
  • Research Site
    Sutton
    SM2 5PT
  • Research Site
    Oxford
    OX3 7LE
  • Research Site
    London
    NW3 2QG
  • Research Site
    Leeds
    LS9 7TF
  • Research Site
    Leicester
    LE1 5WW
  • Research Site
    London
    SE1 9RT
  • Research Site
    Taunton
    TA1 5DA
  • Research Site
    Aberdeen
    AB25 2ZN
  • Research Site
    Shrewsbury
    SY3 8XQ
  • Research Site
    Ipswich
    IP4 5PD
  • Research Site
    Northampton
    NN1 5BD
  • Research Site
    Lancaster
    LA1 4RP
  • Research Site
    Warwick
    CV34 5BW
  • Research Site
    Derby
    DE22 3NE
  • Research Site
    Liverpool
    L7 8YA
  • Research Site
    London
    SW2 6JJ
  • Research Site
    Stockton
    TS19 8PE
  • Research Site
    Sutton In Ashfield
    NG17 4JL
  • Research Site
    Burton-on-Trent
    DE13 0RB
  • Research Site
    Whitchurch
    CF14 2TL
  • Research Site
    Bath
    BA1 3NG
  • Research Site
    Reading
    RG1 5AN
  • Research Site
    Guilford
    GU27XX
  • Research Site
    Brighton
    BN2 5BD

AstraZeneca Clinical Study Information Center 1-877-240-9479
information.center@astrazeneca.com


AstraZeneca Breast Cancer Study Locator Service 1-877-400-4656
az-bcsl@careboxhealth.com



The study is sponsored by AstraZeneca and is in collaboration with Austrian Breast and Colorectal Cancer Study Group (ABCSG).



We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: NCT05952557
Last updated 25 March 2025

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top